You are here: Industry Insights > RV001

News List

RhoVac retains international investment bank as advisor for desired RV001 transaction prnasia
October 13, 2021
RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today, October 11, 2021, that it has retained the services of Stifel Nicolaus Europe Limited ("Stifel"), a global investment bank...
Clean interim safety review of RhoVac's clinical phase IIb study in prostate cancer prnasia
July 12, 2021
RhoVac AB, a Swedish cancer immunotherapy company, announces on July 9th 2021, that its Safety Monitoring Committee has conducted a planned interim safety review of its clinical phase IIb trial in prostate cancer, known as BRaVac.
Mount Sinai Hospital in New York joins RhoVac's Phase IIb Study in Prostate Cancer prnasia
April 22, 2021
RhoVac AB, a Swedish cancer immunotherapy company, announces, April 21st 2021, that the prestigious Mount Sinai hospital in New York is initiated as the latest addition to US trial centres in RhoVac's clinical phase IIb study, "BRaVac", in prostate cancer
Global Covid-19 Vaccination Roll-out causes delay to RhoVac's Phase IIb study prnasia
March 09, 2021
RhoVac AB, a Swedish cancer immunotherapy company, announces today, March 8th , 2021, that its clinical phase IIb study, "BRaVac", in prostate cancer, will be somewhat further delayed as Covid-19 vaccinations are rolled out to the study population.
RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA prnasia
November 25, 2020
RhoVac, a clinical stage company today announced that the American FDA has granted Fast Track Designation to the company's drug candidate, RV001.